Laurus Labs Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹2,206 Cr +33.5% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
LL

Laurus Labs Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Laurus Labs Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,778Cr
+25.7% YoY
+7.6% QoQ
Net profit
₹252Cr
+171% YoY
+29.9% QoQ
Margin
27%
+7 pp YoY
+3 pp QoQ

Laurus Labs Ltd Q3 FY26 key numbers

Revenue
ARV segment revenues expected to remain in the range of Rs. 2,500 to 3,000 crores.

As stated in Laurus Labs Ltd's Q3 FY26 earnings call transcript · published 8 Aug 2026. Reported figures, not investment advice.

Price₹1,802
Market cap₹96.6K Cr
P/E88.3

Revenue & Sales Performance

  • API and formulation segments expected to grow significantly in FY’28, with some growth in FY’27 due to new capacities and validations. (Page 21)
  • ARV segment revenues expected to remain in the range of Rs. 2,500 to 3,000 crores. (Page 21)
  • Generic API business growth viewed as very sustainable; FDF business growth also expected to be sustainable due to new capacities and volume gains. (Pages 15, 21)
  • CDMO business reported 50% growth in 9 months FY’26; expects continued healthy growth in Q4 FY’26 and qualitative growth in FY’27 driven mainly by commercial supplies. (Pages 12, 14)
  • Non-ARV formulations expected to sustain growth supported by additional capacities for CMO partners in Europe and new launches in North America. (Page 19)

2 more points from Laurus Labs Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Laurus Labs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • New greenfield CAPEX of 500 acres in Atchutapuram: land allotment expected in Q4 FY'26; CAPEX to start in second half of FY'27; qualification and validation expected two years later (around FY'29).
  • Joint venture with Krka Pharma: Phase-1 includes 3 billion solid oral tablet capacity and 100 million potent tablet capacity; Phase-1 expected completion by mid-2027; Phase-2 to add 5 billion solid oral tablet capacity.
  • Peptide CDMO commercial manufacturing facility: qualification expected during calendar year 2026; integrated capacity being created including amino acids and peptide processing.
  • ADC (antibody drug conjugates) GMP facility: $25 million allocated for construction; no meaningful revenue expected in next two years; investments ongoing in both CAPEX and OPEX.

2 more points from Laurus Labs Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Laurus Labs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • It's mentioned that the CDMO business has strong recurring business from existing long-term customer relationships and a healthy pipeline with a well-balanced mix of big pharma, mid-, and small-sized biotechs.
  • The company supplies multiple commercial molecules and is investing in capacity expansion, including peptides and advanced technologies.
  • For human health CDMO, several programs with partners are ongoing with commercial supplies.

2 more points from Laurus Labs Ltd's call on order book

Create a free account to keep reading this call

Laurus Labs Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Laurus Labs Ltd Q3 FY26 results — key figures

Laurus Labs Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue1,7781,415+25.7%1,653+7.6%
Operating profit (EBITDA)480285+68.4%403+19.1%
Operating margin27%20%+7 pp24%+3 pp
Profit before tax327131+149.6%270+21.1%
Net profit (PAT)25293+171%194+29.9%
EPS (₹)4.661.71+172.5%3.61+29.1%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.2K Cr, net profit ₹436 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Laurus Labs Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What is Laurus Labs Ltd share price analysis?

Laurus Labs Ltd currently shows a neutral. The stock trades at a P/E of 88.3 with a market cap of ₹96,570 Cr. Investors should review the full earnings analysis for detailed insights.

Is Laurus Labs Ltd planning capital expenditure?

New greenfield CAPEX of 500 acres in Atchutapuram: land allotment expected in Q4 FY'26; CAPEX to start in second half of FY'27; qualification and validation expected two years later (around FY'29).

Keep Laurus Labs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.